Vin, In addition to the cellular immunity/CTL topic, I'd be interested in your take on the anti-viral therapeutics landscape, especially as it relates to Covid.
One I've been following loosely for some years is a new 'biomimetic' approach that mimics the body's own innate defensin protein system. Currently in Phase 2 trial for Covid, with data due Aug/Sept timeframe.
Brilacidin not only works against bacteria like MRSA, but also as a broad spectrum anti-viral. A big plus is that by mimicking the body's defensin protein system, the odds of bacterial or viral resistance developing should be extremely small -
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.